Showing results (991-1000 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|August 24, 2026
Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four-period replicated crossover studyNakyong Lee, Joo-Youn Cho, Byungwook Kim
Clinical Pharmacology in Drug Development|October 22, 2026
Pharmacokinetics and Safety Evaluation of the Transglutaminase 2 Inhibitor Suvigletistat in Healthy Chinese, Japanese, and White/European ParticipantsRomina A Nand, Hannah Woodcock, Kasia A Okrojek-Swiderek, et al.
Clinical Pharmacology in Drug Development|October 23, 2026
A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male SubjectsJianxin Wang, Kai Gu, Mingxuan Zhang, et al.
Clinical Pharmacology in Drug Development|November 4, 2022
Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal ImpairmentCathrine Leonowens, Virginia Schmith, Jie Zhou, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without DasabuvirAkshanth R Polepally, Sandeep Dutta, Beibei Hu, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein TranslationMarla Weetall, Thomas Davis, Gary Elfring, et al.
Clinical Pharmacology in Drug Development|June 9, 2016
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in HumansCharles D Meyers, Adele Noe, Atish Salunke, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
A Thorough QT Study of Teduglutide in Healthy SubjectsManfred Hartmann, Wolfgang Timmer, Armin Schultz, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance StudyMonette M Cotreau, Christine L Hale, Lindsey Jacobson, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
The Effect of Food on Cysteamine Bitartrate Absorption in Healthy ParticipantsRanjan Dohil, Betty L Cabrera, Jon Gangoiti, et al.
Pageof 136